Supply Chain Intelligence

MetaVia Inc. Supply Chain

MTVA supply chain intelligence for MetaVia Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

MTVA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

14Suppliers
0Customers
3Debt Items
20Related Chains

MetaVia Inc. Suppliers

TickerNameConfidenceEvidence
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. …
AZN AstraZeneca PLC 72% ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or…
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from BMY graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered u…
BMY Bristol-Myers Squibb Company 72% ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market…
BMYMP Bristol-Myers Squibb Co 72% ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or…
GALT Galectin Therapeutics Inc. 72% ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or…
GALT Galectin Therapeutics Inc. 72% Reciprocal relationship from GALT graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from GALT graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from GALT g…
GLMD Galmed Pharmaceuticals Ltd. 72% ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or…
GLMD Galmed Pharmaceuticals Ltd. 72% Reciprocal relationship from GLMD graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market.…
IONS Ionis Pharmaceuticals, Inc. 72% Reciprocal relationship from IONS graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered…
IONS Ionis Pharmaceuticals, Inc. 72% ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or…
VKTX Viking Therapeutics, Inc. 72% ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our securities in connection with investments or…
VKTX Viking Therapeutics, Inc. 72% Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from MTVA graph: Reciprocal relationship from VKTX g…

MetaVia Inc. Customers

No clients on recordNo downstream customers found in our database for MetaVia Inc..

MetaVia Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
MTVA-DEBT-11127 Warrants outstanding: 993204 90% xbrl warrant detail from xbrl 2025-12-31.
MTVA-DEBT Debt stack $194,000 90% Market cache reports total debt of $194,000.
MTVA-DEBT-11128 Xbrl Convertible 90% xbrl convertible detail from xbrl 2019-12-31.

MetaVia Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for MetaVia Inc..

MetaVia Inc. Ownership

HolderNameConfidenceEvidence
MTVA-OWNER-MORGAN-STANLEY Morgan Stanley 95% 13F/ownership overlay lists Morgan Stanley; shares held 1,860; ownership 0.04%; value $2,622; as of 2025-12-31.
MTVA-OWNER-TOWER-RESEARCH-CAPITAL-LLC-TRC Tower Research Capital LLC (TRC) 95% 13F/ownership overlay lists Tower Research Capital LLC (TRC); shares held 244; value $344; as of 2025-12-31.
MTVA-OWNER-UBS-GROUP-AG UBS Group AG 95% 13F/ownership overlay lists UBS Group AG; shares held 1,300; ownership 0.03%; value $1,832; as of 2025-12-31.
MTVA-OWNER-BANK-OF-AMERICA-CORPORATION Bank of America Corporation 95% 13F/ownership overlay lists Bank of America Corporation; shares held 8; value $11; as of 2025-12-31.
MTVA-OWNER-CITADEL-ADVISORS-LLC Citadel Advisors Llc 95% 13F/ownership overlay lists Citadel Advisors Llc; shares held 12,192; ownership 0.24%; value $17,190; as of 2025-12-31.
MTVA-OWNER-JPMORGAN-CHASE-CO JPMORGAN CHASE & CO 95% 13F/ownership overlay lists JPMORGAN CHASE & CO; shares held 22; value $31; as of 2025-12-31.
MTVA-OWNER-BLACKROCK-INC Blackrock Inc. 95% 13F/ownership overlay lists Blackrock Inc.; shares held 479; ownership 0.01%; value $675; as of 2025-12-31.
MTVA-OWNER-BROWN-BROTHERS-HARRIMAN-CO Brown Brothers Harriman & Co 95% 13F/ownership overlay lists Brown Brothers Harriman & Co; shares held 2; value $2; as of 2025-12-31.
MTVA-OWNER-VANGUARD-GROUP-INC Vanguard Group Inc 95% 13F/ownership overlay lists Vanguard Group Inc; shares held 20,088; ownership 0.39%; value $28,324; as of 2025-12-31.
MTVA-OWNER-SBI-SECURITIES-CO-LTD SBI Securities Co., Ltd. 95% 13F/ownership overlay lists SBI Securities Co., Ltd.; shares held 141; value $198; as of 2025-12-31.

MetaVia Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
AZN AstraZeneca PLC 100.00 1 ['supplier']
GLMD Galmed Pharmaceuticals Ltd. 100.00 1 ['supplier']
IONS Ionis Pharmaceuticals, Inc. 100.00 1 ['supplier']
GALT Galectin Therapeutics Inc. 100.00 1 ['supplier']
VKTX Viking Therapeutics, Inc. 100.00 1 ['supplier']
BMYMP Bristol-Myers Squibb Co 100.00 1 ['supplier']
BMY Bristol-Myers Squibb Company 100.00 1 ['supplier']
EMMA Emmaus Life Sciences, Inc. 50.00 2
FATE Fate Therapeutics, Inc. 50.00 2
CTNM Contineum Therapeutics, Inc. 50.00 2
CCCC C4 Therapeutics, Inc. 50.00 2
BEAM Beam Therapeutics Inc. 50.00 2
BCYC Bicycle Therapeutics plc 50.00 2
CHRS Coherus Oncology, Inc. 50.00 2
LGNZZ LIGAND PHARMACEUTICALS INC 50.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 50.00 2
FULC Fulcrum Therapeutics, Inc. 50.00 2
LGND Ligand Pharmaceuticals Incorporated 50.00 2
BHC Bausch Health Companies Inc. 50.00 2
CYTK Cytokinetics, Incorporated 50.00 2
View MTVA supply chain intel →

Explore the full interactive supply chain map for MetaVia Inc..

Open MTVA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map